Investigational Drug Information for MT-7117
✉ Email this page to a colleague
What is the development status for investigational drug MT-7117?
MT-7117 is an investigational drug.
There have been 11 clinical trials for MT-7117.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2020.
The most common disease conditions in clinical trials are Protoporphyria, Erythropoietic, Scleroderma, Systemic, and Scleroderma, Diffuse. The leading clinical trial sponsors are Mitsubishi Tanabe Pharma Development America, Inc., Mitsubishi Tanabe Pharma Corporation, and [disabled in preview].
Summary for MT-7117
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2020-06-01) |
| Vendors | 16 |
Recent Clinical Trials for MT-7117
| Title | Sponsor | Phase |
|---|---|---|
| Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 1 |
| Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 3 |
| Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects | Mitsubishi Tanabe Pharma Development America, Inc. | Phase 1 |
Clinical Trial Summary for MT-7117
Top disease conditions for MT-7117
Top clinical trial sponsors for MT-7117
US Patents for MT-7117
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
